Histogen Inc. (HSTO)
| Market Cap | 5.40M |
| Revenue (ttm) | 3.77M |
| Net Income (ttm) | -11.11M |
| Shares Out | 4.27M |
| EPS (ttm) | -3.46 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 64,262 |
| Open | 1.22 |
| Previous Close | 1.20 |
| Day's Range | 1.20 - 1.27 |
| 52-Week Range | 0.76 - 9.40 |
| Beta | 0.99 |
| Analysts | Buy |
| Price Target | 2.04 (+61.91%) |
| Earnings Date | May 11, 2023 |
About HSTO
Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, whi... [Read more]
Financial Performance
In 2022, Histogen's revenue was $3.77 million, an increase of 265.21% compared to the previous year's $1.03 million. Losses were -$11.11 million, -25.69% less than in 2021.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for HSTO stock is "Buy." The 12-month stock price forecast is $2.04, which is an increase of 61.91% from the latest price.
News
Why Is Histogen (HSTO) Stock Up 37% Today?
Histogen (NASDAQ: HSTO) stock is rising higher on Friday after getting a patent for CTS-2090. The patent is titled “Caspase Inhibitors and Methods of Use Thereof.
Histogen Announces Issuance of US Patent Covering CTS-2090 Methods of Use
The Newly Issued Patent is Expected to Provide Protection into 2040
Histogen Reports Year-End 2022 Results and Provides Business Update
Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory Diseases Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory D...
Histogen Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing its pan-caspase and caspase selective inhibitors as treatments fo...
Amerimmune LLC Maintains Intellectual Property on the COVID-19 Related Use of Caspase Inhibitors as a Result of Histogen Inc. Led Arbitration
MCLEAN, Va.--(BUSINESS WIRE)--Amerimmune LLC is a translational medicine biotechnology firm focused on discovery and rapid development of novel therapies for diseases, including COVID-19.
Histogen (HSTO) Upgraded to Strong Buy: Here's What You Should Know
Histogen (HSTO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Histogen Hires Alfred P. Spada Ph.D.
Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory Diseases Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory D...
Histogen Reports Third Quarter 2022 Financial Results and Provides Business Update
SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics for orthopedic indications and pan-...
Histogen Reports Second Quarter 2022 Financial Results and Provides Business Update
Closed $5M Financing in July
Histogen to Report Second Quarter 2022 Financial Results and Provide Business Update
SAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selecti...
Histogen Announces Closing of $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules
SAN DIEGO, July 14, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selecti...
Histogen Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules
SAN DIEGO, July 12, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selecti...
Why Is Histogen (HSTO) Stock Soaring 35% Today?
Histogen (HSTO) stock is rocketing higher on Tuesday despite a lack of news concerning the clinical-stage therapeutics company. The post Why Is Histogen (HSTO) Stock Soaring 35% Today?
Histogen Announces 1-for-20 Reverse Stock Split
SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selecti...
Histogen to Present at the H.C. Wainwright Global Investment Conference
SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selectiv...
Histogen Reports First Quarter 2022 Financial Results and Provides Business Update
Received $3.75 Million Payment from Allergan
CORRECTING and REPLACING Paracrine Announces Appointment of Biotech Veteran David H. Crean, Ph.D.
SAN DIEGO--(BUSINESS WIRE)--Please replace the release with the following corrected version due to multiple revisions. The updated release reads: PARACRINE ANNOUNCES APPOINTMENT OF BIOTECH VETERAN DAV...
Paracrine Announces Appointment of Biotech Veteran David Crean, Ph.D. to the Board of Directors
SAN DIEGO--(BUSINESS WIRE)--Paracrine, Inc., a company developing its novel cell therapy platform in late-stage clinical trials in advanced wound care, announced today the appointment of David Crean, ...
Histogen to Report First Quarter 2022 Financial Results and Provide Business Update
SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase select...
Histogen Announces Closing of $4.75 Million Private Placement
SAN DIEGO, March 25, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage company focused on developing potential first-in-class restorative therapeutics that ignite the body's natu...
Histogen Announces $4.75 Million Private Placement
SAN DIEGO, March 23, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage company focused on developing potential first-in-class restorative therapeutics that ignite the body's natu...
Histogen Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update
Phase 1/2 Study of HST 003 for Cartilage Regeneration in the Knee Ongoing with Top-Line Data Anticipated in the First Half of 2023 Phase 1/2 Study of HST 003 for Cartilage Regeneration in the Knee Ong...
Histogen to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Business Update
SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite th...
Histogen Announces Closing of $3.5 Million Private Placement
SAN DIEGO, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage company focused on developing potential first-in-class restorative therapeutics that ignite the body's natur...
Histogen Announces $3.5 Million Private Placement
SAN DIEGO, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage company focused on developing potential first-in-class restorative therapeutics that ignite the body's natur...